International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Multiple Myeloma (MM)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Blood Cancer J

Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y

doi: 10.1038/s41408-025-01259-z

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

Further Publications

Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumour Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group

Clin Cancer Res

Dhawan A, Baitamouni S, Liu D, Yehia L, Anthony K, McCarther A, Tischkowitz M, MacFarland SP, Ngeow J, Hoogerbrugge N, Eng C

doi: 10.1158/1078-0432.CCR-24-3819

Head and Neck Cancer

Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations

Lancet Oncol

Abou-Foul AK, Henson C, Chernock RD, Huang SH, Lydiatt WM, McDowell L, O'Sullivan B, Perez-Ordonez B, Robinson M, Nankivell PC, Ruiz-Bravo E, Chiosea SI, Green TM, Hunter KD, Hwang JS, Koljenovic S, Koppes SA, Larsen SR, Lo AWI, Costes-Martineau V, Mittal N, Mori T, Nagao T, Panayiotides IG, Pinto CAL, Scheckenbach K, Seethala RR, Ulhøi BP, Vingiani A, Zhang Y, Yom SS, Mehanna H

doi: 10.1016/S1470-2045(24)00143-8

ASH 2024

Multiple Myeloma (MM)

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Head and Neck Cancer

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Lancet Oncol

Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS, HNCIG

doi: 10.1016/S1470-2045(24)00068-8

ASH 2024

Multiple Myeloma (MM)

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Risk of infections in multiple myeloma. A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry

Haematologica

Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, Knut-Bojanowska D, Larfors G, Turesson I, Villegas-Scivetti M, Sverrisdóttir I

doi: 10.3324/haematol.2024.285645

Multiple Myeloma (MM)

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

J Clin Oncol

Kaiser MF, Sonneveld P, Cairns DA, Raab MS, San-Miguel Izquierdo J, Zhang R, Acosta J, Larocca A, Popat R, Li C, Baertsch MA, Brown SR, Lahuerta Palacios J, Gandhi AK, Macé S, Musto P, Yong K, Mai EK, Dubin F, Blade J, Capra A, Cook G, Bertsch U, Mateos MV, Boccadoro M, Jackson GH, Gutiérrez NC, Gay F, Weinhold N

doi: 10.1200/JCO-24-01253

Related content

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumour Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group

Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Risk of infections in multiple myeloma. A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma